Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | The treatment of patients with t(11;14) myeloma

Susan Bal • 10 Jun 2023
EHA 2023
Multiple Myeloma

Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, comments on the biology and treatment of t(11;14) multiple myeloma, highlighting the efficacy of BCL-2 inhibition and immunotherapy in this subset of patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Susan Bal

1:31
BCL2 inhibition with sonrotoclax for treating t(11;14) multiple myeloma
Susan Bal • 9 Dec 2023
2:09
Using MRD to understand the response to autoSCT in patients with multiple myeloma
Susan Bal • 9 Dec 2023
1:42
Immune profiling & MRD negativity of NDMM treated with quadruplet induction+autoSCT: MILESTONE trial
Susan Bal • 9 Dec 2023
2:14
BMS-986393 CAR T-cell therapy for R/R multiple myeloma: results of a Phase I trial
Susan Bal • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals